Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

Waiting for news of the Alfasigma trial with Brilacidin. It should be time. But if Ipix is speaking with other companies about a gastrointestinal license for Brilacidin maybe Alfasigma does not do the trial. I do not know how long Alfasigma has for response to a Right of First Refusal request if another company is interested in Brilacidin for gastrointestinal.

A reminder this one wee indication for Brilacidin is worth USD$24 million plus royalties. $24 million is more than the total today market value of Ipix. The market is not always correct.

“We are thrilled to forge this partnership with Innovation Pharmaceuticals,” said Pier Vincenzo Colli, Chief Executive Officer at Alfasigma. “The Phase 2 Brilacidin clinical study results in UP/UPS look promising and reflective of Brilacidin’s unique drug properties and treatment potential."
https://www.globenewswire.com/news-release/2019/07/22/1885838/0/en/Innovation-Pharmaceuticals-Announces-License-Agreement-with-Alfasigma-S-p-A-for-the-Development-and-Commercialization-of-Brilacidin-in-Ulcerative-Proctitis-Ulcerative-Proctosigmoid.html